March 2026
1. RICAURTE-FAJARDO A, Garcia Gonzalez K, Merino Campo S, Alvarado-De la Hoz C, et al
   Integrated determinants of multiple sclerosis susceptibility: Genetics, environment, infection and the microbiota.
   J Neurol Sci. 2026;484:125865.
   

   >> Share

   
   
2. YOUNG CA, Rog D, Tanasescu R, Sharrack B, et al
   Fatigue prevalence, interactions with associated symptoms and longitudinal changes in those with multiple sclerosis: Insights from the TONiC study.
   J Neurol Sci. 2026;484:125853.
   

   >> Share

   
   
3. IANNIELLO A, Piervincenzi C, Pozzilli C, Satriano F, et al
   A proof-of-concept study on the relationship between lifetime Estrogen exposure, menopausal transition, and neurodegeneration in women with multiple sclerosis.
   J Neurol Sci. 2026;484:125854.
   

   >> Share

   
   February 2026
4. IANNIELLO A, Barbuti E, Capobianco MF, Tranfa M, et al
   Predictors of short-term, relapse-independent progression in multiple sclerosis: A machine learning approach based on clinical data and conventional MRI-derived features.
   J Neurol Sci. 2026;483:125846.
   

   >> Share

   
   
5. UROLAGIN D, Kavyashree MV, Sowmya BA
   Comment on "Plasma neurofilament light chain to evaluate response during cladribine treatment in multiple sclerosis".
   J Neurol Sci. 2026 Feb 18:125820. doi: 10.1016/j.jns.2026.125820.
   

   >> Share

   
   
6. ALBITES COEN B, Chowdhury P, Messina SA, Keegan BM, et al
   Brain MRI to detect cervical spinal cord critical demyelinating lesions in progressive MS.
   J Neurol Sci. 2026;481:125761.
   

   >> Share

   
   
7. GUIDO FS, Chen JJ, Decker PA, Fereidan-Esfahani M, et al
   The impact of adding optical coherence tomography in MS diagnostic criteria on the classification of tumefactive demyelination.
   J Neurol Sci. 2026;481:125739.
   

   >> Share

   
   
8. NICOLELLA V, Terracciano D, Moccia M
   Authors response to Comment on "Plasma neurofilament light chain to evaluate response during cladribine treatment in multiple sclerosis".
   J Neurol Sci. 2026;482:125819.
   

   >> Share

   
   
9. KARNBROCK L, Herwerth M, Bloemberg GV, Huber M, et al
   Persistent parvovirus B19 DNAemia in B-cell depletion: Implications for family planning in multiple sclerosis and related disorders.
   J Neurol Sci. 2026;482:125796.
   

   >> Share

   
   
10. BAHARNOORI M, Glanz B, Polgar-Turcsanyi M, Saxena S, et al
    Correlation between blood biomarkers and patient-reported outcomes (PROs) of depression and mental health scores in individuals with multiple sclerosis (iwMS).
    J Neurol Sci. 2026;482:125786.
    

    >> Share

    
    January 2026
11. AERTS S, Geys L, Severijns D, Alkhawajah M, et al
    Directions for advancing prognostic assessments in multiple sclerosis: Qualitative Insights from MS specialist Interviews.
    J Neurol Sci. 2026;481:125756.
    

    >> Share

    
    December 2025
12. JAKIMOVSKI D, Bergsland N, Marr K, Dwyer MG, et al
    Lower vascular cerebral flow and cerebral perfusion may be associated with impairment of the glymphatic system in multiple sclerosis: A cross-sectional DTI-ALPS MRI study.
    J Neurol Sci. 2025;480:125709.
    

    >> Share

    
    
13. TYAGI B, Toppo L, Biradar A
    Comment on "wearing-off symptoms persist in the majority of patients with multiple sclerosis after switching from natalizumab to ocrelizumab".
    J Neurol Sci. 2025;480:125705.
    

    >> Share

    
    
14. FUCHS L, Avizov R, Karni A, Golan M, et al
    Siponimod enhances brain-derived neurotrophic factor secretion from immune cells in multiple sclerosis: A longitudinal study.
    J Neurol Sci. 2025;480:125699.
    

    >> Share

    
    
15. RANGANI F, Nahayati MA, Pahlevan Kakhki M, Aghaee-Bakhtiari SH, et al
    Ocrelizumab modulates the IL-2 signaling pathway and associated lncRNAs in multiple sclerosis.
    J Neurol Sci. 2025;480:125693.
    

    >> Share

    
    
16. NICOLELLA V, Varelli M, Fasano S, Cantone E, et al
    Plasma neurofilament light chain to evaluate response during cladribine treatment in multiple sclerosis.
    J Neurol Sci. 2025;480:125681.
    

    >> Share

    
    November 2025
17. GELISSEN LMY, Hogenboom L, Toorop AA, Strijbis EMM, et al
    Wearing-off symptoms persist in the majority of patients with multiple sclerosis after switching from natalizumab to ocrelizumab.
    J Neurol Sci. 2025;479:125652.
    

    >> Share

    
    
18. CWAJNA M, Hamouda AM, Kendall N, Ghozy S, et al
    Factors influencing timeliness of reporting results from multiple sclerosis related clinical trials to ClinicalTrials.gov.
    J Neurol Sci. 2025;479:123744.
    

    >> Share

    
    October 2025
19. PIEDRABUENA MA, Correale J, Silva B, Fiol M, et al
    Efficacy and safety of Cladribine as a therapeutic option in multiple sclerosis patients over 50 years of age: A real-world study.
    J Neurol Sci. 2025;478:123727.
    

    >> Share

    
    
20. SPIERER R, Hurani M, Stein N, Rawashdeh A, et al
    Trends in prevalence and incidence of multiple sclerosis in the Israeli Jewish and Arab populations.
    J Neurol Sci. 2025;478:123721.
    

    >> Share

    
    September 2025
21. MOODY SN, Manuel M, Willette A, Shirtcliff E, et al
    Corrigendum to "The intersection of race and sex on the clinical and cognitive progression of multiple sclerosis" [Journal of the Neurological Sciences, 466 (2024) 123260].
    J Neurol Sci. 2025;478:123697.
    

    >> Share

    
    
22. SIPILA J, Jokela M, Solje E
    Municipality-level incidence of clinically diagnosed amyotrophic lateral sclerosis, multiple sclerosis and Parkinson's disease.
    J Neurol Sci. 2025;478:123696.
    

    >> Share

    
    August 2025
23. LADAKIS DC, Ghajarzadeh M, Bhargava P, Absinta M, et al
    Association of paramagnetic rim lesions with patient-reported neuropsychiatric symptoms in multiple sclerosis.
    J Neurol Sci. 2025;477:123657.
    

    >> Share

    
    July 2025
24. ABBADESSA G, Schiavetti I, Bollo L, Cellerino M, et al
    Safety assessment of switching from fingolimod to siponimod: An Italian multicenter prospective study.
    J Neurol Sci. 2025;474:123533.
    

    >> Share

    
    June 2025
25. GLANZ BI, Kletenik I, Singhal T, Zurawski JD, et al
    Subjective cognitive function in individuals with multiple sclerosis: Associations with objective cognitive function, anxiety, depression, and fatigue.
    J Neurol Sci. 2025;475:123593.
    

    >> Share

    
    
26. KVARTSKHAVA T, Freudenstein D, Sarmiento N, Angstwurm K, et al
    Ocrelizumab as first-line therapy in highly active relapsing-remitting multiple sclerosis.
    J Neurol Sci. 2025;475:123577.
    

    >> Share

    
    
27. NOVARELLA F, Nicolella V, Fiorenza M, Falco F, et al
    Neurofilament light chain and Alzheimer pathology biomarkers in elderly people with multiple sclerosis.
    J Neurol Sci. 2025;475:123562.
    

    >> Share

    
    May 2025
28. DEVOGELAERE J, Van Remoortel A, Van Laethem D, Faille LD, et al
    Impact of brain volume on coronavirus disease of 2019 severity and subsequent cognitive decline in patients with multiple sclerosis.
    J Neurol Sci. 2025;475:123552.
    

    >> Share

    
    
29. NYGAARD MKE, Riemenschneider M, Gaemelke T, Dalgas U, et al
    Spatiotemporal alterations of gray matter microstructure in newly diagnosed relapsing-remitting multiple sclerosis patients: A longitudinal diffusion kurtosis MRI study.
    J Neurol Sci. 2025;474:123551.
    

    >> Share

    
    
30. KELLY H, Sun R, Elkasaby M, Wang A, et al
    Movement disorders in relapsing and progressive MS: A comprehensive prospective evaluation of a large real-life cohort.
    J Neurol Sci. 2025;472:123468.
    

    >> Share

    
    
31. ZIVLAEI N, Asani DC, Trier NH, Ziogiene D, et al
    Virus-specific antibody responses in multiple sclerosis patients treated with Ocrevus.
    J Neurol Sci. 2025;474:123537.
    

    >> Share

    
    
32. BERNTSSON SG, Reis J, Zjukovskaja C, Tulek Z, et al
    Climate change impacts the symptomology and healthcare of multiple sclerosis patients through fatigue and heat sensitivity - A systematic review.
    J Neurol Sci. 2025;474:123526.
    

    >> Share

    
    March 2025
33. RISI M, Altieri M, Bisecco A, Rippa V, et al
    Longitudinal assessment of cognitive function in patients with non-relapsing MOG-IgG associated disease.
    J Neurol Sci. 2025;470:123413.
    

    >> Share

    
    
34. RANGANI F, Rakhshi N, Kadkhoda Mezerji Z, Alikhah A, et al
    Association of IL2RA and multiple sclerosis risk: A case control, systematic review, and meta-analysis study.
    J Neurol Sci. 2025;472:123461.
    

    >> Share

    
    February 2025
35. HELMLINGER B, Seebacher B, Ropele S, Hechenberger S, et al
    Effects of rhythmic-cued gait training on gait-like task related brain activation in people with multiple sclerosis.
    J Neurol Sci. 2025;471:123426.
    

    >> Share

    
    
36. FILIPPATOU A, Theodorou A, Stefanou MI, Tzanetakos D, et al
    Optical coherence tomography and angiography in multiple sclerosis: A systematic review and meta-analysis.
    J Neurol Sci. 2025;470:123422.
    

    >> Share

    
    
37. WANG WS, Xia ZY
    Examining the role of optical coherence tomography in multiple sclerosis research and clinical practice.
    J Neurol Sci. 2025;470:123421.
    

    >> Share

    
    January 2025
38. YOUNG CA, Rog D, Sharrack B, Chhetri SK, et al
    Clinical and socio-demographic characteristics of people with multiple sclerosis at the time of diagnosis: Influences on outcome trajectories.
    J Neurol Sci. 2025;470:123409.
    

    >> Share

    
    
39. MIRMOSAYYEB O, Yazdan Panah M, Moases Ghaffary E, Vaheb S, et al
    The relationship between optical coherence tomography and magnetic resonance imaging measurements in people with multiple sclerosis: A systematic review and meta-analysis.
    J Neurol Sci. 2025;470:123401.
    

    >> Share

    
    
40. NOCITI V, Romozzi M, Annovazzi P, Fantozzi R, et al
    Effectiveness, safety, and impact on multiple sclerosis course of anti-CGRP monoclonal antibodies.
    J Neurol Sci. 2025;469:123392.
    

    >> Share

    
    
41. GOPALAKRISHNAN N, Cadden M, Barker L, Healy BC, et al
    Baseline predictors of cross-sectional and longitudinal performance on the symbol digit modalities test in individuals with multiple sclerosis.
    J Neurol Sci. 2025;469:123384.
    

    >> Share

    
    
42. ENGELS D, Flierl-Hecht A, Shalaginova G, Rek S, et al
    Multiple sclerosis twin study reveals distinct genetic, disease-specific, and psychometric impact on coping with critical life events.
    J Neurol Sci. 2025;469:123381.
    

    >> Share

    
    December 2024
43. D'CUNHA MA, Pandit L, Sudhir A
    MRZ-reaction maybe influenced by immunization status and is not exclusive to multiple sclerosis.
    J Neurol Sci. 2024;468:123365.
    

    >> Share

    
    
44. MIMORI M, Katsumoto A, Okamoto T, Sato W, et al
    Ofatumumab for multiple sclerosis with disability accumulation.
    J Neurol Sci. 2024;468:123356.
    

    >> Share

    
    November 2024
45. NOMURA T, Muramatsu K, Yaguchi H, Uwatoko H, et al
    Three cases of multiple sclerosis presenting with palmoplantar pustulosis while receiving ofatumumab.
    J Neurol Sci. 2024;467:123315.
    

    >> Share

    
    
46. KORNILOV SA, Price ND, Gelinas R, Acosta J, et al
    Multi-Omic characterization of the effects of Ocrelizumab in patients with relapsing-remitting multiple sclerosis.
    J Neurol Sci. 2024;467:123303.
    

    >> Share

    
    September 2024
47. MOODY SN, Manuel M, Willette A, Shirtcliff E, et al
    The intersection of race and sex on the clinical and cognitive progression of multiple sclerosis.
    J Neurol Sci. 2024;466:123260.
    

    >> Share

    
    
48. DOHERTY F, Lynch P, Powell P, Monaghan K, et al
    Feasibility and effectiveness of telerehabilitation on mobility and balance function in multiple sclerosis: A systematic review and meta-analysis.
    J Neurol Sci. 2024;466:123214.
    

    >> Share

    
    August 2024
49. AFZAL SS, Khatri I, Amin SB
    Comment on: Evaluation of the T25FW in minimally disabled people with multiple sclerosis.
    J Neurol Sci. 2024 Aug 22:123189. doi: 10.1016/j.jns.2024.123189.
    

    >> Share

    
    
50. PATEL AM, Exuzides A, Yermilov I, Dalglish H, et al
    Development and validation of a claims-based algorithm to identify patients with Neuromyelitis Optica Spectrum disorder.
    J Neurol Sci. 2024;463:123110.
    

    >> Share

    
    
51. CHAPPELL M, Sanderson A, Arun T, Green C, et al
    Literature review and meta-analysis of natalizumab therapy for the treatment of highly active relapsing remitting multiple sclerosis in the 'suboptimal therapy' patient population.
    J Neurol Sci. 2024;464:123172.
    

    >> Share

    
    
52. GOUIDER R, Souissi A, Mrabet S, Gharbi A, et al
    Environmental factors related to multiple sclerosis progression.
    J Neurol Sci. 2024;464:123161.
    

    >> Share

    
    July 2024
53. WICKS TR, Jakimovski D, Reeves J, Bergsland N, et al
    Comorbid onset of cardiovascular diagnosis and long-term confirmed disability progression in multiple sclerosis: A 15-year follow-up study.
    J Neurol Sci. 2024;464:123156.
    

    >> Share

    
    
54. TOOROP AA, Wessels MHJ, Gelissen LMY, Hoitsma E, et al
    Influence of personalized extended interval dosing on the natalizumab wearing-off effect - a sub-study of the NEXT-MS trial.
    J Neurol Sci. 2024;462:123102.
    

    >> Share

    
    
55. PETROVSKA J, Coynel D, Freytag V, de Quervain DJ, et al
    Polygenic susceptibility for multiple sclerosis is associated with working memory in low-performing young adults.
    J Neurol Sci. 2024;463:123138.
    

    >> Share

    
    
56. NIKITINA V, Santi Laurini G, Montanaro N, Motola D, et al
    Safety of fingolimod in patients with relapsing remitting multiple sclerosis: A descriptive analysis of data from the EudraVigilance database.
    J Neurol Sci. 2024;463:123132.
    

    >> Share

    
    June 2024
57. NICOLELLA V, Fiorenza M, Monteiro I, Novarella F, et al
    Clinical utility of the Lumipulse immunoassay for plasma neurofilament light chain in multiple sclerosis.
    J Neurol Sci. 2024;463:123115.
    

    >> Share

    
    
58. TRIVEDI RR, Archambault AS, Pavlak C, Gastaldi M, et al
    Prevalence of anti-myelin oligodendrocyte glycoprotein antibodies across neuroinflammatory and neurodegenerative diseases.
    J Neurol Sci. 2024;461:123041.
    

    >> Share

    
    
59. HILDEBRANDT H, Eling P
    Comments on energy conservation treatments for MS-related fatigue and a new proposal.
    J Neurol Sci. 2024;461:123040.
    

    >> Share

    
    
60. HELMLINGER B, Pinter D, Hechenberger S, Bachmaier G, et al
    Evaluation of the T25FW in minimally disabled people with multiple sclerosis.
    J Neurol Sci. 2024;462:123073.
    

    >> Share

    
    May 2024
61. FERNANDES L, Coats RO, Mon-Williams M, Hafeez A, et al
    A novel tool for characterising upper limb function in progressive multiple sclerosis through kinematic assessment.
    J Neurol Sci. 2024;462:123068.
    

    >> Share

    
    
62. MANNI A, Oggiano F, Palazzo C, Panetta V, et al
    Clinical and biological predictors of Cladribine effectiveness in Multiple Sclerosis: A real-world, single Centre study considering a two-year interval from year-2 dosing.
    J Neurol Sci. 2024;462:123070.
    

    >> Share

    
    
63. LOREFICE L, Piras C, Sechi V, Barracciu MA, et al
    Spinal cord MRI activity in multiple sclerosis: Predictive value for relapses and impact on treatment decisions.
    J Neurol Sci. 2024;462:123057.
    

    >> Share

    
    
64. PIEDRABUENA MA, Correale J, Fiol M, Marrodan M, et al
    Selection of disease modifying therapies in multiple sclerosis based on patient's age and disease activity: Data from a nationwide registry.
    J Neurol Sci. 2024;461:123052.
    

    >> Share

    
    
65. JAKIMOVSKI D, Qureshi F, Ramanathan M, Jalaleddini K, et al
    Glial cell injury and atrophied lesion volume as measures of chronic multiple sclerosis inflammation.
    J Neurol Sci. 2024;461:123055.
    

    >> Share

    
    
66. SKARLIS C, Papadopoulos V, Raftopoulou S, Mavragani CP, et al
    Association of B-cell activating factor gene variants with serum anti-JCV antibody positivity in male patients with multiple sclerosis under natalizumab treatment: Implications for progressive multifocal leukoencephalopathy risk stratification.
    J Neurol Sci. 2024;461:123046.
    

    >> Share

    
    March 2024
67. CHAER LER, de Mendonca JM, Del Negro MC, Titze-de-Almeida R, et al
    Differential diagnosis between multiple sclerosis and leukodystrophies - A scoping review.
    J Neurol Sci. 2024;459:122969.
    

    >> Share

    
    
68. BERNARDES C, Fernandes C, Cunha C, Nunes C, et al
    Natalizumab extended interval dosing: what about wearing-off effect?
    J Neurol Sci. 2024;458:122930.
    

    >> Share

    
    February 2024
69. RECHTMAN A, Zveik O, Haham N, Freidman-Korn T, et al
    Thyroid hormone dysfunction in MOGAD and other demyelinating diseases.
    J Neurol Sci. 2024;457:122866.
    

    >> Share

    
    
70. BALCOM EF, Smyth P, Kate M, Vu K, et al
    Disease-modifying therapy use and health resource utilisation associated with multiple sclerosis over time: A retrospective cohort study from Alberta, Canada.
    J Neurol Sci. 2024;458:122913.
    

    >> Share

    
    
71. KUSNIRIKOVA ZK, Kacirova I, Pesakova V, Hradilek P, et al
    Serum teriflunomide concentrations in routine multiple sclerosis therapy: A cross-sectional pilot study.
    J Neurol Sci. 2024;458:122910.
    

    >> Share

    
    January 2024
72. ZANETTA C, Faustino P, Guerrieri S, Nozzolillo A, et al
    Fast but not furious: Rapid ocrelizumab infusion as a strategy to optimize multiple sclerosis patients' management.
    J Neurol Sci. 2024;457:122897.
    

    >> Share

    
    
73. MOTEGI H, Kufukihara K, Kitagawa S, Sekiguchi K, et al
    Non-lesional white matter changes depicted by q-space diffusional MRI correlate with clinical disabilities in multiple sclerosis.
    J Neurol Sci. 2024;456:122851.
    

    >> Share

    
    
74. HJAERESEN S, Benedikz E, Sejbaek T, Axelsson M, et al
    High temperature requirement A1 and macrophage migration inhibitory factor in the cerebrospinal fluid; a potential marker of conversion from relapsing-remitting to secondary progressive multiple sclerosis.
    J Neurol Sci. 2024;457:122888.
    

    >> Share

    
    
75. RAGHIB MF, Bao F, Elkhooly M, Bernitsas E, et al
    Choroid plexus volume as a marker of retinal atrophy in relapsing remitting multiple sclerosis.
    J Neurol Sci. 2024;457:122884.
    

    >> Share

    
    December 2023
76. KREITER D, Postma AA, Hupperts R, Gerlach O, et al
    Hallmarks of spinal cord pathology in multiple sclerosis.
    J Neurol Sci. 2023;456:122846.
    

    >> Share

    
    
77. MARANTOS T, Kyriazopoulou E, Lekakis V, Voumvourakis KI, et al
    Immunogenicity and safety of vaccines in multiple sclerosis: A systematic review and meta-analysis.
    J Neurol Sci. 2023;456:122852.
    

    >> Share

    
    
78. DOHERTY F, Powell P, McBride C, Monaghan K, et al
    Physical Telerehabilitation interventions for Gait and balance in Multiple sclerosis: A Scoping review.
    J Neurol Sci. 2023;456:122827.
    

    >> Share

    
    November 2023
79. KHORMI I, Al-Iedani O, Alshehri A, Ramadan S, et al
    MR myelin imaging in multiple sclerosis: A scoping review.
    J Neurol Sci. 2023;455:122807.
    

    >> Share

    
    
80. JAKIMOVSKI D, Kavak KS, Zakalik K, McGraw C, et al
    Patient-reported outcomes based on discontinuation or continuous treatment with natalizumab: New York State Multiple Sclerosis Consortium (NYSMSC) study.
    J Neurol Sci. 2023;455:122781.
    

    >> Share

    
    
81. DITTEL LJ, Dittel BN, Brod SA
    Ingested (oral) adrenocorticotropic hormone (ACTH) inhibits interleukin-17 in the central nervous system after adoptive transfer of T helper (Th)1/Th17 T cells in the mouse model of multiple sclerosis, experimental autoimmune encephalomyelitis.
    J Neurol Sci. 2023;456:122779.
    

    >> Share

    
    October 2023
82. MIRMOSAYYEB O, Yazdan Panah M, Mokary Y, Ghaffary EM, et al
    Optical coherence tomography (OCT) measurements and disability in multiple sclerosis (MS): A systematic review and meta-analysis.
    J Neurol Sci. 2023;454:120847.
    

    >> Share

    
    
83. HECHENBERGER S, Helmlinger B, Penner IK, Pirpamer L, et al
    Psychological factors and brain magnetic resonance imaging metrics associated with fatigue in persons with multiple sclerosis.
    J Neurol Sci. 2023;454:120833.
    

    >> Share

    
    September 2023
84. DE LURY AD, Bisulca JA, Lee JS, Altaf MD, et al
    Magnetic resonance imaging detection of deep gray matter iron deposition in multiple sclerosis: A systematic review.
    J Neurol Sci. 2023;453:120816.
    

    >> Share

    
    
85. MUSTAFA R, Flanagan EP, Duffy DJ, Weinshenker BG, et al
    Laboratory evaluation for the differential diagnosis of possible multiple sclerosis in the United States: A physician survey.
    J Neurol Sci. 2023;453:120781.
    

    >> Share

    
    August 2023
86. OSEN A, Stefoski D, Shoemaker T, Kaplan T, et al
    Cyclophosphamide for severe acute forms of central nervous system inflammatory disorders.
    J Neurol Sci. 2023;451:120693.
    

    >> Share

    
    July 2023
87. PATIL SA, Joseph B, Tagliani P, Sastre-Garriga J, et al
    Corrigendum to "Longitudinal stability of inter-eye differences in optical coherence tomography measures for identifying unilateral optic nerve lesions in multiple sclerosis" [Journal of the Neurological Sciences 449C (2023) Start page-End page/JOTNS
    J Neurol Sci. 2023 Jul 17:120695. doi: 10.1016/j.jns.2023.120695.
    

    >> Share

    
    
88. JEANTIN L, Boudot de la Motte M, Deschamps R, Gueguen A, et al
    Natalizumab extended-interval dosing in a real-life setting.
    J Neurol Sci. 2023;450:120689.
    

    >> Share

    
    
89. WEBB LM, Cacciaguerra L, Krecke KN, Chen JJ, et al
    Marked central canal T2-hyperintensity in MOGAD myelitis and comparison to NMOSD and MS.
    J Neurol Sci. 2023;450:120687.
    

    >> Share

    
    May 2023
90. PATIL SA, Joseph B, Tagliani P, Sastre-Garriga J, et al
    Longitudinal stability of inter-eye differences in optical coherence tomography measures for identifying unilateral optic nerve lesions in multiple sclerosis.
    J Neurol Sci. 2023;449:120669.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share